First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor. SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ...

I240501. Mentor: Dr. Martin Young, Division of Cardiovascular Disease “Mechanisms of Hypertension and Cardiovascular Diseases” (Funding Source: NIH/NHLBI) One postdoctoral fellowship is available ...

This grant is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number(s) Catalyze NIH/NHLBI 1R61HL156152-01A1 and Catalyze NIH/NHLBI ...

Balu-Iyer awarded $1.5 million NHLBI/NIH grant to develop hemophilia treatment Sathy Balu-Iyer, PhD, professor, Department of Pharmaceutical Sciences, has devoted much of his career to furthering ...

NIH NHLBI Division of Intramural Research (DIR), United States of America (USA) Time frame: 1 January 2023 - 31 December 2023 ...

The NHLBI Pooled Cohorts Study was supported by NIH/NHLBI awards R21HL121457, R21HL129924, and K23HL130627. For full details on funding information, please see the published journal article.

Gao and Forno: The current grant from the NIH/NHLBI will allow us to recruit over 700 children and adults, both healthy and with various airway conditions including asthma, COPD and cystic fibrosis.

Meanwhile, the $8 million in funding was announced on May 9; this tranche of funding brings the total raised to $17.5 million, excluding the aforementioned NIH grant award. Orlando Health Ventures ...

2021-2024, Sensitivity of the Circadian Clock to the Spectrum of Evening Light in Early Childhood; Lauren Hartstein, PI, F32-HD103393; NIH/NHLBI, Primary Mentor 2020-2025, Advancing Engagement and ...

Article ‘Count’ and ‘Share’ for NIH NHLBI Division of Intramural Research (DIR) based on listed parameters only. According to the parameters selected above, there are no articles from NIH ...